|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,051 USD | +0.02% |
|
-0.20% | +19.67% |
June 26 (Reuters) - The U.S. Food and Drug Administration has given its approval for a treatment from Verona Pharma for a chronic lung disease that commonly affects smokers, the U.K.-based company said on Wednesday. (Reporting by Pratik Jain and Sruthi Narasimha Chari in Bengaluru; Editing by Pooja Desai)
Price
|
Change
|
5d. change
|
Capi.
| ||
|---|---|---|---|---|---|
| 1,051 USD | +0.02% | -0.20% | 113B | ||
| 89.94 EUR | +0.09% | +2.65% | 120B | ||
| 14.46 USD | -6.35% | -3.60% | 1.17B | ||
| 1st Jan change | Capi. | |
|---|---|---|
| +19.67% | 113B | |
| +15.20% | 121B | |
| +18.95% | 26.02B | |
| -23.86% | 19.39B | |
| -19.03% | 15.91B | |
| -20.90% | 15.09B | |
| -46.14% | 15.06B | |
| +63.85% | 14.93B | |
| +4.49% | 13.85B | |
| +116.20% | 10.8B |
REGENERON PHARMACEUTICALS, INC. 
